Details for Patent: 7,737,142

Which drugs does patent 7,737,142 protect, and when does it expire?

Patent 7,737,142 protects VRAYLAR and is included in one NDA.

Protection for VRAYLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 7,737,142

Title:	(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Abstract:	The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
Inventor(s):	Eva Againe Csongor, Janos Galambos, Katalin Nogradi, Istvan Vago, Istvan Gyertyan, Bela Kiss, Istvan Laszlovszky, Judit Laszy, Katalin Saghy
Assignee:	Richter Gedeon Nyrt
Application Number:	US11/337,275
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,737,142
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,737,142

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-005	Dec 18, 2025		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-006	Dec 18, 2025		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-003	Sep 17, 2015		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-004	Sep 17, 2015		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 7,737,142

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Hungary	P0302451	Aug 4, 2003

International Family Members for US Patent 7,737,142

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1663996		PA2017027	Lithuania
European Patent Office	1663996		CR 2017 00042	Denmark
European Patent Office	1663996		122017000083	Germany
European Patent Office	1663996		300913	Netherlands
European Patent Office	1663996		47/2017	Austria
European Patent Office	1663996		LUC00039	Luxembourg
European Patent Office	1663996		2017C/045	Belgium